6.3
Adrenerge Receptoren:ɑ subtype
Adrenoceptoren worden ingedeeld in α- en ꞵ klassen op basis van hun potentie voor catecholamine-agonisten. α-adrenoceptoren vertonen de volgende volgo…
ɑ-adrenoceptors show higher affinity to Adr and NA than ISO.
They are classified into ɑ1 and ɑ2 subtypes based on various factors.
Upon stimulation, ɑ1 receptors activate phospholipase C , releasing IP3 and DAG as secondary messengers.
They are present in the postsynaptic effector organs, particularly the smooth muscles of the cardiovascular and GI systems, and are responsible for vasoconstriction, increased blood pressure, and GI muscle relaxation.
ɑ2 receptor stimulation inhibits adenylyl cyclase, decreases cAMP production, and modulates ion channels.
They are predominantly present in autonomic nerve terminals, pancreatic beta cells, vascular smooth muscles, and platelets. They affect the release of autonomic neurotransmitters and insulin, vascular smooth muscles contraction and platelet aggregation.
ɑ1 and ɑ2 receptors are subdivided into three subtypes based on subtype-selective drugs. For instance, tamsulosin—used for treating prostatic hyperplasia—preferentially inhibits ɑ1-A receptors in the prostate gland over ɑ1-B receptors in blood vessels, so they have fewer cardiovascular side effects.
View the full transcript and gain access to JoVE Core videos
Q1: What is the difference between α1 and α2 adrenergic receptors?
α1 receptors are located postsynaptically on effector organs and activate phospholipase C, releasing IP3 and DAG as secondary messengers, causing vasoconstriction and increased blood pressure. α2 receptors are predominantly presynaptic on nerve terminals and pancreatic beta cells, inhibiting adenylyl cyclase to decrease cAMP production, modulating neurotransmitter release and insulin secretion.
Q2: How do α1 receptors affect smooth muscle in the cardiovascular and GI systems?
α1 receptor stimulation activates the phospholipase C pathway, releasing IP3 and DAG as secondary messengers. In cardiovascular smooth muscle, this causes vasoconstriction and increased blood pressure. In GI smooth muscle, α1 activation leads to muscle relaxation, reducing GI motility and contractions.
Q3: What are the main locations and functions of α2 adrenergic receptors?
α2 receptors are predominantly located on autonomic nerve terminals, pancreatic beta cells, vascular smooth muscles, and platelets. Upon stimulation, they inhibit adenylyl cyclase and decrease cAMP production, modulating the release of autonomic neurotransmitters and insulin, controlling vascular smooth muscle contraction, and affecting platelet aggregation.
Q4: Why does tamsulosin have fewer cardiovascular side effects than other α-blockers?
Tamsulosin preferentially inhibits α1-A receptors in the prostate gland over α1-B receptors in blood vessels. This receptor subtype selectivity allows the drug to treat prostatic hyperplasia effectively while minimizing cardiovascular effects like hypotension that occur when α1-B receptors in blood vessels are blocked.
Q5: How do α1 and α2 receptors differ in their catecholamine potency?
Both α1 and α2 receptors show higher affinity for adrenaline and noradrenaline than isoprenaline. However, α1 receptors are classified based on their postsynaptic location and phospholipase C activation, while α2 receptors are classified by their presynaptic location and adenylyl cyclase inhibition, reflecting distinct functional roles in the autonomic nervous system.
Q6: What are the three subtypes of α1 and α2 receptors?
α1 receptors are subdivided into α1-A, α1-B, and α1-D subtypes, while α2 receptors are subdivided into α2-A, α2-B, and α2-C subtypes. These subdivisions are based on subtype-selective drugs and their differential tissue distribution, allowing for more precise pharmacological targeting and understanding of drug-receptor selectivity.
Q7: How does α2 receptor stimulation affect ion channels and cAMP levels?
α2 receptor activation inhibits adenylyl cyclase, decreasing intracellular cAMP production and causing closure of ion channels. This mechanism contrasts with α1 receptors, which activate phospholipase C. The reduced cAMP and ion channel closure modulate autonomic neurotransmitter release and regulate vascular smooth muscle and platelet function.